Shopping Cart 0
Cart Subtotal
USD 0

Iovance Biotherapeutics Inc (IOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company's lead product candidate, LN-144 is an autologous, ready-to-infuse cell therapy. The product is an adoptive cell therapy using TIL technology and is being investigated in Phase II trials for the treatment of patients with metastatic melanoma, recurrent and metastatic squamous cell carcinoma of the neck and head and recurrent and metastatic or persistent cervical cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

Iovance Biotherapeutics Inc (IOVA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Lion Biotechnologies Raises USD100 Million in Financing 12

Partnerships 14

RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 14

Iovance Biotherapeutics Enters into Research Agreement with Arthur G. James Cancer Hospital & Richard J Solove Research Institute 15

Lion Biotech Enters into Agreement with MD Anderson Cancer Center 16

Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 17

Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 18

Lion Biotech Enters into Research Agreement with MedImmune 19

Lion Biotech Enters into Agreement with WuXi AppTec 20

Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 21

Merger 22

Genesis Biopharma And Lion Biotech Merge 22

Licensing Agreements 23

Lion Biotechnologies Enters into Licensing Agreement with PolyBioCept 23

Lion Biotech Enters into Licensing Agreement with National Institutes of Health 24

Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 25

Equity Offering 26

Iovance Biotherapeutics Raises USD252.2 Million in Public Offering of Shares 26

Iovance Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 27

Iovance Biotherapeutics Raises USD57.5 Million in Public Offering of Shares 29

Lion Biotechnologies Raises USD47.5 Million in Public Offering of Shares 31

Lion Biotech Raises USD73.6 Million in Public Offering of Shares 32

Lion Biotech Raises USD34.5 Million in Public Offering of Shares 34

Lion Biotech Completes Private Placement Of Units For USD 23.3 Million 36

Genesis Biopharma Completes Private Placement Of Shares For USD 1.1 Million 38

Iovance Biotherapeutics Inc-Key Competitors 39

Iovance Biotherapeutics Inc-Key Employees 40

Iovance Biotherapeutics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Nov 06, 2018: Iovance Biotherapeutics reports third quarter 2018 financial results and provides corporate update 42

Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update 45

May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 47

Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 49

Oct 31, 2017: Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results 51

Aug 01, 2017: Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results 54

May 01, 2017: Lion Biotechnologies Reports First Quarter 2017 Financial Results 56

Mar 07, 2017: Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 58

Corporate Communications 60

Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors 60

Aug 08, 2017: Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer 61

May 25, 2017: Lion Biotechnologies Announces Departure of Chief Financial Officer 62

Product Approvals 63

Aug 31, 2017: Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma 63

Clinical Trials 64

Jun 07, 2018: Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma 64

Jan 24, 2018: Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers 65

Nov 09, 2017: Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting 66

Nov 09, 2017: Iovance Biotherapeutics Announces Presentation on Its cancer Drug candidate LN-145 at SITC Meeting 68

Oct 11, 2017: Iovance Biotherapeutics to Present Abstracts on Tumor-infiltrating Lymphocyte Therapy (LN-144) at 2017 SITC Annual Meeting 69

Oct 11, 2017: Iovance Biotherapeutics to Present Abstracts on Tumor-infiltrating Lymphocyte Therapy (LN-145) at 2017 SITC Annual Meeting 70

Sep 13, 2017: Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer 71

Aug 16, 2017: Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer 72

Jun 05, 2017: Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial 73

Jun 01, 2017: Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer 74

May 19, 2017: Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma 75

May 17, 2017: Lion Biotechnologies to Present New Data from Ongoing LN-144 Phase 2 Clinical Trial at 2017 American Society of Clinical Oncology Annual Meeting 76

Apr 18, 2017: Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer 77

Other Significant Developments 78

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 78

Dec 13, 2017: Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017 79

Jun 27, 2017: Lion Biotechnologies Changes Name to Iovance Biotherapeutics 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Iovance Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Lion Biotechnologies Raises USD100 Million in Financing 12

RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 14

Iovance Biotherapeutics Enters into Research Agreement with Arthur G. James Cancer Hospital & Richard J Solove Research Institute 15

Lion Biotech Enters into Agreement with MD Anderson Cancer Center 16

Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 17

Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 18

Lion Biotech Enters into Research Agreement with MedImmune 19

Lion Biotech Enters into Agreement with WuXi AppTec 20

Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 21

Genesis Biopharma And Lion Biotech Merge 22

Lion Biotechnologies Enters into Licensing Agreement with PolyBioCept 23

Lion Biotech Enters into Licensing Agreement with National Institutes of Health 24

Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 25

Iovance Biotherapeutics Raises USD252.2 Million in Public Offering of Shares 26

Iovance Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 27

Iovance Biotherapeutics Raises USD57.5 Million in Public Offering of Shares 29

Lion Biotechnologies Raises USD47.5 Million in Public Offering of Shares 31

Lion Biotech Raises USD73.6 Million in Public Offering of Shares 32

Lion Biotech Raises USD34.5 Million in Public Offering of Shares 34

Lion Biotech Completes Private Placement Of Units For USD 23.3 Million 36

Genesis Biopharma Completes Private Placement Of Shares For USD 1.1 Million 38

Iovance Biotherapeutics Inc, Key Competitors 39

Iovance Biotherapeutics Inc, Key Employees 40

Iovance Biotherapeutics Inc, Other Locations 41

Iovance Biotherapeutics Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Iovance Biotherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.